FEATURED EDITORIAL
The search for supply chain partners goes on. Intensely. But productively? Are we missing anything? We are about to learn the answer to that is yes. Alan Davis, President & CEO, i5 Services says puzzling is how little these searches vary – and he's concerned that invariance has negative national supply-chain implications. He has a mission and a search platform to change that.
- For Bispecific Ab Programs, Measure Twice And Outsource Once
- What Goes Into Restarting A Shelved Orphan Drug Candidate?
- A Much-Improved Approach For Understanding And Managing Safety Risks
- Outsourcing Growth, And The Cold (Storage Monitoring) Truth
- CSV Assumes The AI System Sits Still — It Doesn't.
- Lower Court Agrees With WuXi AppTec (And Many Of Us)
- Mission-Driven Professionals And Students Build America's Supply Chains
GUEST COLUMNISTS
-
A Much-Improved Approach For Understanding And Managing Safety Risks
Learn how causal mechanism and effect analysis (CMEA) and its principles can be used to develop and maintain safer working environments in the pharma/biotech and medical device industries.
-
CSV Assumes The AI System Sits Still — It Doesn't.
The computer system validation playbook was written for software that holds its shape. AI doesn't. Validating it has to become an act of governance.
-
July Update — U.S. Generic Drug Tariffs: Implications For Pharma And Outsourcing
Mathini Ilancheran updates us on how delayed U.S. tariffs on generic drug imports could reshape supply, sourcing, and trial planning.
-
In Bioprocessing, Trusted Data Is A Process Variable
As digital systems become increasingly interconnected, digital validation ensures systems generating and managing GxP data remain accurate, consistent, and trustworthy.
-
Combination Cell Therapy's Clinical Success Hinges On Manufacturability
Cell therapy could help unlock checkpoint inhibitors’ potential in solid tumors, but combination regimens raise the bar for manufacturing consistency and scalability.
-
Are Biopharma Companies Outsourcing Their Ability To Think?
Amid gaining immediate access to external manufacturing capabilities, sponsor companies can lose the foundational understanding required to govern that capability.
-
June 2026 — CDMO Opportunities And Threats Report
Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.
-
The Decision Rights Matrix: Making Sponsor-CDMO Governance Enforceable
In LVV manufacturing, the quality target product profile and the DRM are designed to work together. One defines what is being governed, the other names who governs it.
PHARMA OUTSOURCING WHITE PAPERS
-
Fast Path To Market: Going From GMP1 To PPQ In Just 12 Months
Learn how focused optimization and coordinated execution helped overcome technical uncertainty and enable faster progression to market readiness.
-
Building Local Biomanufacturing Capacity In South Africa
Biovac evolved from a vaccine supplier to a biopharmaceutical innovator, providing a blueprint for expanding Africa's vaccine manufacturing capacity. Gain valuable insights from their journey.
-
A Comprehensive Solution For Adventitious Agent Testing
Modern sequencing methods offer sensitive detection of adventitious and species‑specific viruses. Learn how targeted and non‑targeted NGS approaches improve confidence in cell bank characterization.
-
Developing Effective Procedures
Effective procedure development starts with understanding the purpose and should integrate change management, risk management, and knowledge management to ensure a robust quality system.
-
FDA's Regenerative Medicine Advanced Therapy (RMAT) Program
RMAT qualification requires preliminary clinical evidence demonstrating the potential to address an unmet medical need. This designation grants benefits like intensive guidance and faster FDA review.
-
Using Client Centricity As Fuel For Innovative Biologics Development And Manufacturing Solutions
Complex biologics require flexible development, advanced analytics, and quality by design. Learn how collaborative bioprocessing reduces risk, enables efficient scale‑up, and supports clinical success.
PHARMA OUTSOURCING APP NOTES & CASE STUDIES
NEWSLETTER ARCHIVE
- 08.24.26 -- STREAM: Small Molecules, Big Impact Across Drug Development
- 08.24.26 -- The U.S. Supply-Chain Uncovered: A Superior Search For Domestic Suppliers
- 08.21.26 -- Strengthen Quality, Safety, And Regulatory Readiness
- 08.21.26 -- Why Is Biopharma Left Out Of The U.S. Infrastructure Conversation?
REPORTING
PRODUCTS & SERVICES
ON-DEMAND WEBINARS
- Selecting A Test Method For Your Container System
- When Unexpected Particles Threaten Your Biologic
- Life Cycle Assessment (LCA): Empowering Sustainable Decisions
- Controlling Nitrosamine Risk In Drug Products: Detection, Formation, And Control Strategies
- Enhancing AAV Manufacturing Yield Via Mini-Helper Plasmid